<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39358866</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>Impaired mucosal IgA response in patients with severe COVID-19.</ArticleTitle><Pagination><StartPage>2401940</StartPage><MedlinePgn>2401940</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2401940</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2024.2401940</ELocationID><Abstract><AbstractText>Several studies have investigated the antibody response to SARS-CoV-2, focusing particularly on the systemic humoral immune response and the production of immunoglobulin G (IgG) antibodies. IgA antibodies play a crucial role in protecting against respiratory viral infections but have also been associated with the pathophysiology of COVID-19. We performed a prospective study of 169 COVID-19 patients - 50 with critical/severe (ICU), 47 with moderate (Non-ICU), and 72 with asymptomatic COVID-19 - to explore the humoral immune response to SARS-CoV-2 infection. We found that the early systemic IgA response strongly induced in patients with severe disease did not block IgG neutralization functions and activated FcRs more effectively than IgG. However, even if SIgA levels were high, mucosal IgA antibodies could not control the infection effectively in patients with severe disease. Our findings highlight the complexity of the immune response to SARS-CoV-2 exhibiting high systemic levels of IgA with strong neutralizing capacity in severe cases, together with higher levels of IgA-FcR activation than in asymptomatic patients. They also suggest the need for further research to fully understand the role of IgA and its structural alterations in mucosal tissues in cases of severe disease and the impact of these antibodies on disease progression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yaugel-Novoa</LastName><ForeName>Melyssa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5444-9135</Identifier><AffiliationInfo><Affiliation>Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, CIRI - Centre International de Recherche en Infectiologie, Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noailly</LastName><ForeName>Blandine</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, CIRI - Centre International de Recherche en Infectiologie, Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jospin</LastName><ForeName>Fabienne</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, CIRI - Centre International de Recherche en Infectiologie, Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pizzorno</LastName><ForeName>Andrés</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0918-6804</Identifier><AffiliationInfo><Affiliation>Team VirPath, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, CIRI - Centre International de Recherche en Infectiologie, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Traversier</LastName><ForeName>Aurélien</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1874-3075</Identifier><AffiliationInfo><Affiliation>Team VirPath, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, CIRI - Centre International de Recherche en Infectiologie, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pozzetto</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-2603-8467</Identifier><AffiliationInfo><Affiliation>Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, CIRI - Centre International de Recherche en Infectiologie, Saint-Etienne, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Agents and Hygiene Department, University Hospital of Saint-Etienne, Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waeckel</LastName><ForeName>Louis</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-4941-2415</Identifier><AffiliationInfo><Affiliation>Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, CIRI - Centre International de Recherche en Infectiologie, Saint-Etienne, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Department, University Hospital of Saint-Etienne, Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Longet</LastName><ForeName>Stéphanie</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5026-431X</Identifier><AffiliationInfo><Affiliation>Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, CIRI - Centre International de Recherche en Infectiologie, Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pillet</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, CIRI - Centre International de Recherche en Infectiologie, Saint-Etienne, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Agents and Hygiene Department, University Hospital of Saint-Etienne, Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Botelho-Nevers</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2773-7750</Identifier><AffiliationInfo><Affiliation>Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, CIRI - Centre International de Recherche en Infectiologie, Saint-Etienne, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Department, University Hospital of Saint-Etienne, Saint-Etienne, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIC 1408 Inserm Vaccinology, University Hospital of Saint-Etienne, Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosa-Calatrava</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Team VirPath, Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, CIRI - Centre International de Recherche en Infectiologie, Lyon, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bourlet</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, CIRI - Centre International de Recherche en Infectiologie, Saint-Etienne, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Agents and Hygiene Department, University Hospital of Saint-Etienne, Saint-Etienne, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paul</LastName><ForeName>Stéphane</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-8830-4273</Identifier><AffiliationInfo><Affiliation>Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, CIRI - Centre International de Recherche en Infectiologie, Saint-Etienne, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Department, University Hospital of Saint-Etienne, Saint-Etienne, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIC 1408 Inserm Vaccinology, University Hospital of Saint-Etienne, Saint-Etienne, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lead contact.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="Y">Immunoglobulin A</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="Y">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">IgA</Keyword><Keyword MajorTopicYN="N">lung</Keyword><Keyword MajorTopicYN="N">polyfunctionality</Keyword><Keyword MajorTopicYN="N">severity</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>3</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39358866</ArticleId><ArticleId IdType="pmc">PMC11451292</ArticleId><ArticleId IdType="doi">10.1080/22221751.2024.2401940</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO  Coronavirus (COVID-19) Dashboard|WHO Coronavirus (COVID-19) Dashboard With Vaccination Data n.d. https://covid19.who.int/ (accessed March 17, 2022).</Citation></Reference><Reference><Citation>Cervia C, Nilsson J, Zurbuchen Y, et al. . Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allergy Clin Immunol. 2021;147:545–557.e9. doi:10.1016/j.jaci.2020.10.040</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.10.040</ArticleId><ArticleId IdType="pmc">PMC7677074</ArticleId><ArticleId IdType="pubmed">33221383</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuentes-Villalobos F, Garrido JL, Medina MA, et al. . Sustained antibody-dependent NK cell functions in mild COVID-19 outpatients during convalescence. Front. Immunol. 2022;13:796481. doi:10.3389/fimmu.2022.796481</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.796481</ArticleId><ArticleId IdType="pmc">PMC8859986</ArticleId><ArticleId IdType="pubmed">35197972</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Falk AJ, Klingström J, et al. . SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. PLoS One. 2022;17:e0262169. doi:10.1371/journal.pone.0262169</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262169</ArticleId><ArticleId IdType="pmc">PMC8754314</ArticleId><ArticleId IdType="pubmed">35020778</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzi L, Dalla Gasperina D, Veronesi G, et al. . Mucosal immune response in BNT162b2 COVID-19 vaccine recipients. EBioMedicine. 2022;75:103788. doi:10.1016/j.ebiom.2021.103788</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103788</ArticleId><ArticleId IdType="pmc">PMC8718969</ArticleId><ArticleId IdType="pubmed">34954658</ArticleId></ArticleIdList></Reference><Reference><Citation>Havervall S, Marking U, Svensson J, et al. . Anti-Spike mucosal IgA protection against SARS-CoV-2 omicron infection. N Engl J Med. 2022;387:1333–1336. doi:10.1056/NEJMc2209651</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209651</ArticleId><ArticleId IdType="pmc">PMC9511632</ArticleId><ArticleId IdType="pubmed">36103621</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Erp EA, Luytjes W, Ferwerda G, et al. . Fc-Mediated antibody effector functions during respiratory syncytial virus infection and disease. Front Immunol. 2019;10:548. doi:10.3389/fimmu.2019.00548</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00548</ArticleId><ArticleId IdType="pmc">PMC6438959</ArticleId><ArticleId IdType="pubmed">30967872</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould VMW, Francis JN, Anderson KJ, et al. . Nasal IgA provides protection against human influenza challenge in volunteers with low serum influenza antibody titre. Front Microbiol. 2017;8:900. doi:10.3389/fmicb.2017.00900</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.00900</ArticleId><ArticleId IdType="pmc">PMC5434144</ArticleId><ArticleId IdType="pubmed">28567036</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterlin D, Mathian A, Miyara M, et al. . Iga dominates the early neutralizing antibody response to SARS-CoV-2. Sci. Transl. Med. 2021;13:eabd2223. doi:10.1126/scitranslmed.abd2223</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd2223</ArticleId><ArticleId IdType="pmc">PMC7857408</ArticleId><ArticleId IdType="pubmed">33288662</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkharaan H, Bayati S, Hellström C, et al. . Persisting salivary IgG against SARS-CoV-2 at 9 months after mild COVID-19: a complementary approach to population surveys. J Infect Dis. 2021;224:407–414. doi:10.1093/infdis/jiab256</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab256</ArticleId><ArticleId IdType="pmc">PMC8244549</ArticleId><ArticleId IdType="pubmed">33978762</ArticleId></ArticleIdList></Reference><Reference><Citation>Guemes-Villahoz N, Burgos-Blasco B, Echevarria-Torres PL, et al. . Detection of anti-SARS-CoV-2 antibodies in tears: ocular surface immunity to COVID-19. Arch Soc Esp Oftalmol. 2023;98:397–403. doi:10.1016/J.OFTALE.2023.05.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.OFTALE.2023.05.009</ArticleId><ArticleId IdType="pmc">PMC10223622</ArticleId><ArticleId IdType="pubmed">37247663</ArticleId></ArticleIdList></Reference><Reference><Citation>Liew F, Talwar S, Cross A, et al. . SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine. 2023;87:104402. doi:10.1016/j.ebiom.2022.104402</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104402</ArticleId><ArticleId IdType="pmc">PMC9762734</ArticleId><ArticleId IdType="pubmed">36543718</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen E, Merzon E, Green I, et al. . Selective IgA deficiency and COVID-19. J Allergy Clin Immunol Pract. 2023;11:1936–1938. doi:10.1016/J.JAIP.2023.02.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JAIP.2023.02.016</ArticleId><ArticleId IdType="pmc">PMC9970652</ArticleId><ArticleId IdType="pubmed">36858279</ArticleId></ArticleIdList></Reference><Reference><Citation>Çölkesen F, Kandemir B, Arslan Ş, et al. . Relationship between selective IgA deficiency and COVID-19 prognosis. Jpn J Infect Dis. 2022;75:228–233. doi:10.7883/yoken.JJID.2021.281</Citation><ArticleIdList><ArticleId IdType="doi">10.7883/yoken.JJID.2021.281</ArticleId><ArticleId IdType="pubmed">34588364</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz MJ, Siracusano G, Cottignies-Calamarte A, et al. . Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis. Front Immunol. 2022;13:842468. doi:10.3389/fimmu.2022.842468</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.842468</ArticleId><ArticleId IdType="pmc">PMC9560774</ArticleId><ArticleId IdType="pubmed">36248831</ArticleId></ArticleIdList></Reference><Reference><Citation>Stacey HD, Golubeva D, Posca A, et al. . Iga potentiates NETosis in response to viral infection. Proc Natl Acad Sci U S A. 2021;118(27):e2101497118. doi:10.1073/pnas.2101497118</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2101497118</ArticleId><ArticleId IdType="pmc">PMC8271757</ArticleId><ArticleId IdType="pubmed">34183391</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty S, Gonzalez JC, Sievers BL, et al. . Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. Sci. Transl. Med. 2022;14:eabm7853. doi:10.1126/SCITRANSLMED.ABM7853</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/SCITRANSLMED.ABM7853</ArticleId><ArticleId IdType="pmc">PMC8939764</ArticleId><ArticleId IdType="pubmed">35040666</ArticleId></ArticleIdList></Reference><Reference><Citation>Bye AP, Hoepel W, Mitchell JL, et al. . Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets. Blood. 2021;138:1481–1489. doi:10.1182/blood.2021011871</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2021011871</ArticleId><ArticleId IdType="pmc">PMC8321687</ArticleId><ArticleId IdType="pubmed">34315173</ArticleId></ArticleIdList></Reference><Reference><Citation>Vicente MM, Alves I, Gaifem J, et al. . Altered IgG glycosylation at COVID-19 diagnosis predicts disease severity. Eur J Immunol. 2022;52:946–957. doi:10.1002/eji.202149491</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202149491</ArticleId><ArticleId IdType="pmc">PMC9087392</ArticleId><ArticleId IdType="pubmed">35307819</ArticleId></ArticleIdList></Reference><Reference><Citation>Noailly B, Yaugel-Novoa M, Werquin J, et al. . Antiviral activities of HIV-1-specific human broadly neutralizing antibodies are isotype-dependent. Vaccines (Basel). 2022;10:903. doi:10.3390/vaccines10060903</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10060903</ArticleId><ArticleId IdType="pmc">PMC9227833</ArticleId><ArticleId IdType="pubmed">35746511</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffen U, Koeleman CA, Sokolova MV, et al. . Iga subclasses have different effector functions associated with distinct glycosylation profiles. Nat Commun. 2020;11; doi:10.1038/s41467-019-13992-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-13992-8</ArticleId><ArticleId IdType="pmc">PMC6949214</ArticleId><ArticleId IdType="pubmed">31913287</ArticleId></ArticleIdList></Reference><Reference><Citation>Staats LAN, Pfeiffer H, Knopf J, et al. . Iga2 antibodies against SARS-CoV-2 correlate with NET formation and fatal outcome in severely diseased COVID-19 patients. Cells. 2020;9:2676. doi:10.3390/cells9122676</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9122676</ArticleId><ArticleId IdType="pmc">PMC7764693</ArticleId><ArticleId IdType="pubmed">33322797</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayet R, Michaud E, Nicoli F, et al. . Impact of IgA isoforms on their ability to activate dendritic cells and to prime T cells. Eur J Immunol. 2020;50:1295–1306. doi:10.1002/eji.201948177</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201948177</ArticleId><ArticleId IdType="pubmed">32277709</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Lorenzi JCC, Muecksch F, et al. . Enhanced SARS-CoV-2 neutralization by dimeric IgA. Sci Transl Med. 2020;13:eabf1555. doi:10.1126/scitranslmed.abf1555</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf1555</ArticleId><ArticleId IdType="pmc">PMC7857415</ArticleId><ArticleId IdType="pubmed">33288661</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohn MK, Hall A, Sepiashvili L, et al. . Pathophysiology of COVID-19: mechanisms underlying disease severity and progression. Physiology. 2020;35:288–301. doi:10.1152/physiol.00019.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiol.00019.2020</ArticleId><ArticleId IdType="pmc">PMC7426542</ArticleId><ArticleId IdType="pubmed">32783610</ArticleId></ArticleIdList></Reference><Reference><Citation>Liechti T, Iftikhar Y, Mangino M, et al. . Immune phenotypes that predict COVID-19 severity. Res. Sq. 2022. doi:10.21203/rs.3.rs-1378671/v1</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1378671/v1</ArticleId><ArticleId IdType="pmc">PMC9700777</ArticleId><ArticleId IdType="pubmed">36433939</ArticleId></ArticleIdList></Reference><Reference><Citation>Zervou FN, Louie P, Stachel A, et al. . SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection. J Med Virol. 2021;93:5409–5415. doi:10.1002/jmv.27058</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27058</ArticleId><ArticleId IdType="pmc">PMC8242647</ArticleId><ArticleId IdType="pubmed">33932299</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyara M, Saichi M, Sterlin D, et al. . Pre-COVID-19 immunity to common cold human coronaviruses induces a recall-type IgG response to SARS-CoV-2 antigens without cross-neutralisation. Front. Immunol. 2022;13:790334. doi:10.3389/fimmu.2022.790334</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.790334</ArticleId><ArticleId IdType="pmc">PMC8873934</ArticleId><ArticleId IdType="pubmed">35222375</ArticleId></ArticleIdList></Reference><Reference><Citation>Cagigi A, Yu M, Österberg B, et al. . Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination. JCI Insight. 2021;6(22):e151463. doi:10.1172/jci.insight.151463</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.151463</ArticleId><ArticleId IdType="pmc">PMC8663786</ArticleId><ArticleId IdType="pubmed">34665783</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Yang M, Peng Y, et al. . Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection. Nat Microbiol. 2022;7:423–433. doi:10.1038/s41564-021-01051-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-01051-2</ArticleId><ArticleId IdType="pubmed">35132197</ArticleId></ArticleIdList></Reference><Reference><Citation>Adeniji OS, Giron LB, Purwar M, et al. . COVID-19 severity is associated with differential antibody Fc-mediated innate immune functions. mBio. 2021;12(2):e00281–21. doi:10.1128/mBio.00281-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00281-21</ArticleId><ArticleId IdType="pmc">PMC8092230</ArticleId><ArticleId IdType="pubmed">33879594</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi D, Weng T, Wu J, et al. . Dynamic characteristic analysis of antibodies in patients With COVID-19: a 13-month study. Front. Immunol. 2021;12:708184. doi:10.3389/FIMMU.2021.708184</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FIMMU.2021.708184</ArticleId><ArticleId IdType="pmc">PMC8330131</ArticleId><ArticleId IdType="pubmed">34354712</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al. . Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591:639–644. doi:10.1038/s41586-021-03207-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>den Hartog G, Vos ERA, van den Hoogen LL, et al. . Persistence of antibodies to SARS-CoV-2 in relation to symptoms in a nationwide prospective study. Clin Infect Dis. 2021;73:2155–2162. doi:10.1093/cid/ciab172</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab172</ArticleId><ArticleId IdType="pmc">PMC7929058</ArticleId><ArticleId IdType="pubmed">33624751</ArticleId></ArticleIdList></Reference><Reference><Citation>Magri G, Cerutti A.. Iga summons IgG to take a Hit at HIV-1. Cell Host Microbe. 2020;27:854–856. doi:10.1016/j.chom.2020.05.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.05.017</ArticleId><ArticleId IdType="pmc">PMC8195293</ArticleId><ArticleId IdType="pubmed">32526180</ArticleId></ArticleIdList></Reference><Reference><Citation>Legros V, Denolly S, Vogrig M, et al. . A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021;18:318–327. doi:10.1038/s41423-020-00588-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00588-2</ArticleId><ArticleId IdType="pmc">PMC7786875</ArticleId><ArticleId IdType="pubmed">33408342</ArticleId></ArticleIdList></Reference><Reference><Citation>Noh JY, Yang J-S, Hwang SY, et al. . Duration of humoral immunity and cross-neutralizing activity against the alpha, beta, and delta variants after wild-type SARS-CoV-2 infection: a prospective cohort study. J Infect Dis. 2022;226:975–978. doi:10.1093/INFDIS/JIAC050</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/INFDIS/JIAC050</ArticleId><ArticleId IdType="pmc">PMC8903377</ArticleId><ArticleId IdType="pubmed">35172333</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis SK, Selva KJ, Lopez E, et al. . Heterologous SARS-CoV-2 IgA neutralising antibody responses in convalescent plasma. Clin Transl Immunol. 2022;11:e1424. doi:10.1002/cti2.1424</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1424</ArticleId><ArticleId IdType="pmc">PMC9588388</ArticleId><ArticleId IdType="pubmed">36299410</ArticleId></ArticleIdList></Reference><Reference><Citation>Takamatsu Y, Omata K, Shimizu Y, et al. . SARS-CoV-2-Neutralizing humoral IgA response occurs earlier but Is modest and diminishes faster than IgG response. Microbiol Spectr. 2022;10:e02716–22. doi:10.1128/spectrum.02716-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.02716-22</ArticleId><ArticleId IdType="pmc">PMC9769934</ArticleId><ArticleId IdType="pubmed">36219096</ArticleId></ArticleIdList></Reference><Reference><Citation>Farkash I, Feferman T, Cohen-Saban N, et al. . Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern. Cell Rep. 2021;37:110114. doi:10.1016/j.celrep.2021.110114</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.110114</ArticleId><ArticleId IdType="pmc">PMC8610888</ArticleId><ArticleId IdType="pubmed">34883043</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez J, Edwards K, Chakraborty S, et al. . Proinflammatory IgG Fc structures in patients with severe COVID-19. Nat Immunol. 2021;22:67–73. doi:10.1038/s41590-020-00828-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00828-7</ArticleId><ArticleId IdType="pmc">PMC8130642</ArticleId><ArticleId IdType="pubmed">33169014</ArticleId></ArticleIdList></Reference><Reference><Citation>Ankerhold J, Giese S, Kolb P, et al. . Circulating multimeric immune complexes contribute to immunopathology in COVID-19. Nat Commun. 2022;13:1–15. doi:10.1038/s41467-022-32867-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32867-z</ArticleId><ArticleId IdType="pmc">PMC9513013</ArticleId><ArticleId IdType="pubmed">36163132</ArticleId></ArticleIdList></Reference><Reference><Citation>Haslund-Gourley B, Woloszcuk K, Hou J, et al. . IgM N-glycosylation correlates with COVID-19 severity and rate of complement deposition. Nat Commun. 2024;15(1):404. doi:10.1038/s41467-023-44211-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-44211-0</ArticleId><ArticleId IdType="pmc">PMC10776791</ArticleId><ArticleId IdType="pubmed">38195739</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Ruiz J, Absalón-Aguilar A, Nuñez-Aguirre M, et al. . Neutrophil extracellular traps contribute to COVID-19 hyperinflammation and humoral autoimmunity. Cells. 2021;10:2545. doi:10.3390/cells10102545</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10102545</ArticleId><ArticleId IdType="pmc">PMC8533917</ArticleId><ArticleId IdType="pubmed">34685525</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimpel AK, Maccataio A, Unterweger H, et al. . Iga complexes induce neutrophil extracellular trap formation more potently than IgG complexes. Front. Immunol. 2022;12:761816. doi:10.3389/fimmu.2021.761816</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.761816</ArticleId><ArticleId IdType="pmc">PMC8792984</ArticleId><ArticleId IdType="pubmed">35095840</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes BJ, Adrover JM, Baxter-Stoltzfus A, et al. . Targeting potential drivers of COVID-19: neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652. doi:10.1084/jem.20200652</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200652</ArticleId><ArticleId IdType="pmc">PMC7161085</ArticleId><ArticleId IdType="pubmed">32302401</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldo FB. Role of IgA in IgA nephropathy. J Pediatr. 1990;116:S78–S85. doi:10.1016/S0022-3476(05)82707-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-3476(05)82707-6</ArticleId><ArticleId IdType="pubmed">2184209</ArticleId></ArticleIdList></Reference><Reference><Citation>Allez M, Denis B, Bouaziz JD, et al. . COVID-19-related IgA vasculitis. Arthritis Rheumatol. 2020;72:1952–1953. doi:10.1002/art.41428</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41428</ArticleId><ArticleId IdType="pmc">PMC7361577</ArticleId><ArticleId IdType="pubmed">32633104</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong K, Farooq Alam Shah MU, Khurshid M, et al. . COVID-19 associated vasculitis: a systematic review of case reports and case series. Annals of Medicine &amp; Surgery. 2022;74:103249. doi:10.1016/j.amsu.2022.103249</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.103249</ArticleId><ArticleId IdType="pmc">PMC8754903</ArticleId><ArticleId IdType="pubmed">35039779</ArticleId></ArticleIdList></Reference><Reference><Citation>Junqueira C, Crespo Â, Ranjbar S, et al. . FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. 2022;606:576–584. doi:10.1038/s41586-022-04702-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04702-4</ArticleId><ArticleId IdType="pmc">PMC10071495</ArticleId><ArticleId IdType="pubmed">35385861</ArticleId></ArticleIdList></Reference><Reference><Citation>Fröberg J, Diavatopoulos DA.. Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection. Curr Opin Infect Dis. 2021;34:181–186. doi:10.1097/QCO.0000000000000724</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QCO.0000000000000724</ArticleId><ArticleId IdType="pubmed">33899752</ArticleId></ArticleIdList></Reference><Reference><Citation>Isho B, Abe KT, Zuo M, et al. . Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Sci. Immunol. 2020;5,eabe5511. doi:10.1126/sciimmunol.abe5511</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abe5511</ArticleId><ArticleId IdType="pmc">PMC8050884</ArticleId><ArticleId IdType="pubmed">33033173</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler SE, Crowley AR, Natarajan H, et al. . Distinct features and functions of systemic and mucosal humoral immunity Among SARS-CoV-2 convalescent individuals. Front. Immunol. 2021;11:618685. doi:10.3389/fimmu.2020.618685</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.618685</ArticleId><ArticleId IdType="pmc">PMC7876222</ArticleId><ArticleId IdType="pubmed">33584712</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright PF, Prevost-Reilly AC, Natarajan H, et al. . Longitudinal systemic and mucosal immune responses to SARS-CoV-2 infection. J Infect Dis. 2022;226:1204. doi:10.1093/INFDIS/JIAC065</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/INFDIS/JIAC065</ArticleId><ArticleId IdType="pmc">PMC8903457</ArticleId><ArticleId IdType="pubmed">35188974</ArticleId></ArticleIdList></Reference><Reference><Citation>Bewley KR, Coombes NS, Gagnon L, et al. . Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. Nat Protoc. 2021;16:3114. doi:10.1038/s41596-021-00536-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-021-00536-y</ArticleId><ArticleId IdType="pubmed">33893470</ArticleId></ArticleIdList></Reference><Reference><Citation>Arakawa S, Suzukawa M, Watanabe K, et al. . Secretory immunoglobulin A induces human lung fibroblasts to produce inflammatory cytokines and undergo activation. Clin Exp Immunol. 2019;195:287–301. doi:10.1111/cei.13253</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cei.13253</ArticleId><ArticleId IdType="pmc">PMC6378381</ArticleId><ArticleId IdType="pubmed">30570135</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnett D. Immunoglobulins in the lung. Thorax. 1986;41:337–344. doi:10.1136/thx.41.5.337</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.41.5.337</ArticleId><ArticleId IdType="pmc">PMC1020623</ArticleId><ArticleId IdType="pubmed">3750240</ArticleId></ArticleIdList></Reference><Reference><Citation>Stockley RA, Mistry M, Bradwell AR, et al. . A study of plasma proteins in the sol phase of sputum from patients with chronic bronchitis. Thorax. 1979;34:777–782. doi:10.1136/thx.34.6.777</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.34.6.777</ArticleId><ArticleId IdType="pmc">PMC471196</ArticleId><ArticleId IdType="pubmed">542918</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen AL, Reily C, Novak J, et al. . Immunoglobulin A glycosylation and Its role in disease. Exp Suppl. 2021;112:433–477. doi:10.1007/978-3-030-76912-3_14</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-030-76912-3_14</ArticleId><ArticleId IdType="pubmed">34687019</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization . Clinical management of COVID-19: living guideline. Geneva: World Health Organization; 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">35917394</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaugel-Novoa M, Noailly B, Jospin F, et al. . Prior COVID-19 immunization does not cause IgA- or IgG-dependent enhancement of SARS-CoV-2 infection. Vaccines (Basel). 2023;11:773. doi:10.3390/vaccines11040773</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11040773</ArticleId><ArticleId IdType="pmc">PMC10141984</ArticleId><ArticleId IdType="pubmed">37112685</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzorno A, Padey B, Julien T, et al. . Characterization and treatment of SARS-CoV-2 in nasal and bronchial human airway epithelia. Cell Rep Med. 2020;1:100059. doi:10.1016/J.XCRM.2020.100059</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.XCRM.2020.100059</ArticleId><ArticleId IdType="pmc">PMC7373044</ArticleId><ArticleId IdType="pubmed">32835306</ArticleId></ArticleIdList></Reference><Reference><Citation>Pezzi L, Charrel RN, Ninove L, et al. . Development and evaluation of a Duo SARS-CoV-2 RT-qPCR assay combining two assays approved by the world health organization targeting the envelope and the RNA-dependant RNA polymerase (RdRp) coding regions. Viruses. 2020;12:686. doi:10.3390/v12060686</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12060686</ArticleId><ArticleId IdType="pmc">PMC7354606</ArticleId><ArticleId IdType="pubmed">32630601</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman VM, Landt O, Kaiser M, et al. . Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eurosurveillance. 2020;25:1. doi:10.2807/1560-7917.ES.2020.25.3.2000045</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.3.2000045</ArticleId><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>